In an era where science and technology have advanced at an unprecedented rate, one would expect that the pharmaceutical industry, at the forefront of medical innovation, would be held in high regard. However, there has been a noticeable decline in consumer trust in the drug industry in recent years. This skepticism is not without reason, as various factors have contributed to this erosion of trust.

The global obesity epidemic has prompted significant interest and investment in developing and marketing obesity drugs. With millions worldwide struggling to manage their weight, it’s no surprise that pharmaceutical companies see this as a potentially lucrative market. However, the question arises: Is the market for obesity drugs overvalued? Several factors suggest caution is warranted when evaluating the prospects of obesity drugs.

Pharmacy benefit managers (PBMs) and pharmaceutical companies have been locked in a battle over the cost of prescription drugs for years. PBMs, third-party companies that administer prescription drug benefits for health insurers, argue that they are working to reduce drug costs for patients. Pharmaceutical companies, conversely, say that PBMs are using their market power to extract excessive rebates from drugmakers, which are passed on to patients through higher prices.